Johnson & Johnson starts trial of COVID-19 vaccine after producing immune response in primates – MarketWatch

Johnson & & Johnson
JNJ,
-0.19%.
said Thursday that its lead vaccine candidate protected versus infection with SARS-CoV-2, the infection that triggers COVID-19, in pre-clinical studies. The vaccine … [+719 chars]